Senti Bio spins off lead asset SENTI-202 to a Celadon-controlled private company; stockholders receive CVRs worth up to $60M
SNTI sits 24% above its 52-week low of $0.77 on light trading volume (0.3× avg).
Summary
Senti Bio is spinning off its lead asset SENTI-202 to a Celadon-controlled private company. Stockholders get CVRs worth up to $60M in milestone payments. The remaining public company will focus on early-stage programs with limited cash.
Key Events · M&A and Partnerships · SNTI
-
Spin-Off of Lead Asset SENTI-202
Senti Bio entered into a definitive merger agreement to spin off its lead cancer therapy, SENTI-202, to a private company controlled by Celadon Partners. Stockholders will receive Contingent Value Rights (CVRs) worth up to $60 million in milestone payments.
-
CVR Milestone Structure
The CVRs pay $10M upon BLA filing or acceptance, $20M upon FDA approval, and $30M upon $200M cumulative net sales of SENTI-202, all within seven years. There is no assurance any milestones will be achieved.
-
Remaining Public Company Focus
Post-closing, Senti Bio will focus on early-stage Regulator Dial programs for Rett syndrome and TIL therapies, with only $6.5M in cash as of June 30, 2026, and will need additional financing.
-
Celadon Additional Funding Commitment
Celadon committed to purchase $6M in additional convertible notes, with potential for up to $30M total, which could increase its ownership to 62.3% or 77.5% respectively upon conversion.
Analysis · SNTI · Life Sciences
In a deal that fundamentally restructures the company, Senti Biosciences is spinning off its lead cancer therapy, SENTI-202, to a private company controlled by its largest shareholder, Celadon Partners. Stockholders will receive Contingent Value Rights (CVRs) that could pay up to $60 million if development, regulatory, and sales milestones are met over seven years. The remaining public company will focus on early-stage Regulator Dial programs for Rett syndrome and TIL therapies, with only $6.5 million in cash as of June 30, 2026. Celadon is also committing to purchase $6 million in additional convertible notes, which could increase its ownership to over 62%. The deal requires stockholder approval, including a majority of the minority, and is expected to close in Q3 2026. This transaction separates the most advanced asset from the public entity, leaving stockholders with contingent, uncertain future payouts.
At the time of this filing, SNTI was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.1M. The 52-week trading range was $0.77 to $2.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.